Icotrokinra (JNJ-2113)
Moderate-to-Severe Psoriasis
Key Facts
About Protagonist Therapeutics
Protagonist Therapeutics leverages its proprietary peptide discovery platform to develop innovative therapies for rare and prevalent diseases where current treatments are inadequate. The company has achieved significant clinical milestones with rusfertide nearing NDA filing for polycythemia vera and icotrokinra advancing through Phase 3 trials for psoriasis and other inflammatory conditions through its partnership with Janssen. With multiple programs spanning hematology, immunology, and metabolic diseases, Protagonist is positioned as a leader in peptide therapeutics with potential for multiple near-term commercial launches.
View full company profileAbout Protagonist Therapeutics
Protagonist Therapeutics leverages its proprietary peptide discovery platform to develop innovative therapies for rare and prevalent diseases where current treatments are inadequate. The company has achieved significant clinical milestones with rusfertide nearing NDA filing for polycythemia vera and icotrokinra advancing through Phase 3 trials for psoriasis and other inflammatory conditions through its partnership with Janssen. With multiple programs spanning hematology, immunology, and metabolic diseases, Protagonist is positioned as a leader in peptide therapeutics with potential for multiple near-term commercial launches.
View full company profileAbout Protagonist Therapeutics
Protagonist Therapeutics leverages its proprietary peptide discovery platform to develop innovative therapies for rare and prevalent diseases where current treatments are inadequate. The company has achieved significant clinical milestones with rusfertide nearing NDA filing for polycythemia vera and icotrokinra advancing through Phase 3 trials for psoriasis and other inflammatory conditions through its partnership with Janssen. With multiple programs spanning hematology, immunology, and metabolic diseases, Protagonist is positioned as a leader in peptide therapeutics with potential for multiple near-term commercial launches.
View full company profileAbout Protagonist Therapeutics
Protagonist Therapeutics leverages its proprietary peptide discovery platform to develop innovative therapies for rare and prevalent diseases where current treatments are inadequate. The company has achieved significant clinical milestones with rusfertide nearing NDA filing for polycythemia vera and icotrokinra advancing through Phase 3 trials for psoriasis and other inflammatory conditions through its partnership with Janssen. With multiple programs spanning hematology, immunology, and metabolic diseases, Protagonist is positioned as a leader in peptide therapeutics with potential for multiple near-term commercial launches.
View full company profile